Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sharon O. Azubuike-Osu has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Treatment with Cobra Venom Factor Decreases Ischemic Tissue Damage in Mice

    by Sharon O. Azubuike-Osu, Amelie Kuhs, Philipp Götz, Anna Faro, Klaus T. Preissner, Christoph Arnholdt, Elisabeth Deindl

    Tissue ischemia, caused by the blockage of blood vessels, can result in substantial damage and impaired tissue performance. Information regarding the functional contribution of the complement system in the context of ischemia and angiogenesis is lacking. To investigate the influence of complement activation and depletion upon femoral artery ligation (FAL), Cobra venom factor (CVF) (that functionally resembles C3b, the activated form of complement component C3) was applied in mice in comparison to control mice. Seven days after induction of muscle ischemia through FAL, gastrocnemius muscles of mice were excised and subjected to (immuno-)histological analyses. H&E and apoptotic cell staining (TUNEL) staining revealed a significant reduction in ischemic tissue damage in CVF-treated mice compared to controls. The control mice, however, exhibited a significantly higher capillary-to-muscle fiber ratio and a higher number of proliferating endothelial cells (CD31+/CD45−/BrdU+). The total number of leukocytes (CD45+) substantially decreased in CVF-treated mice versus control mice. Moreover, the CVF-treated group displayed a shift towards the M2-like anti-inflammatory and regenerative macrophage phenotype (CD68+/MRC1+). In conclusion, our findings suggest that treatment with CVF leads to reduced ischemic tissue damage along with decreased leukocyte recruitment but increased numbers of M2-like polarized macrophages, thereby enhancing tissue regeneration, repair, and healing.


  • Open Access

    Cobra Venom Factor Boosts Arteriogenesis in Mice

    by Philipp Götz, Sharon O. Azubuike-Osu, Anna Braumandl, Christoph Arnholdt, Matthias Kübler, Lisa Richter, Manuel Lasch, Lisa Bobrowski, Klaus T. Preissner, Elisabeth Deindl

    Arteriogenesis, the growth of natural bypass blood vessels, can compensate for the loss of arteries caused by vascular occlusive diseases. Accordingly, it is a major goal to identify the drugs promoting this innate immune system-driven process in patients aiming to save their tissues and life. Here, we studied the impact of the Cobra venom factor (CVF), which is a C3-like complement-activating protein that induces depletion of the complement in the circulation in a murine hind limb model of arteriogenesis. Arteriogenesis was induced in C57BL/6J mice by femoral artery ligation (FAL). The administration of a single dose of CVF (12.5 µg) 24 h prior to FAL significantly enhanced the perfusion recovery 7 days after FAL, as shown by Laser Doppler imaging. Immunofluorescence analyses demonstrated an elevated number of proliferating (BrdU+) vascular cells, along with an increased luminal diameter of the grown collateral vessels. Flow cytometric analyses of the blood samples isolated 3 h after FAL revealed an elevated number of neutrophils and platelet-neutrophil aggregates. Giemsa stains displayed augmented mast cell recruitment and activation in the perivascular space of the growing collaterals 8 h after FAL. Seven days after FAL, we found more CD68+/MRC-1+ M2-like polarized pro-arteriogenic macrophages around growing collaterals. These data indicate that a single dose of CVF boosts arteriogenesis by catalyzing the innate immune reactions, relevant for collateral vessel growth.


  • Open Access

    Beneficial Role of Vitexin and Isovitexin Flavonoids in the Vascular Endothelium and Cardiovascular System

    by Sharon O. Azubuike-Osu, Ikenna C. Ohanenye, Claus Jacob, Chukwunonso E.C.C. Ejike, Chibuike C. Udenigwe

    Various medicinal plants contain phenolic compounds, which are useful in the treatment of many diseases. Particularly, vitexin and its isomer, isovitexin, possess many pharmacological effects, including antioxidant, anti-inflammatory, anticancer, antidiabetic, neuroprotective, and antinociceptive activities. Current research has provided evidence for the prospective use of vitexin and isovitexin in the formulation of medicinal products useful in the prevention and treatment of specific ailments. The aim of this review was, therefore, to examine the influence of vitexin and isovitexin on the vascular system as well as the possible mechanisms through which the flavonoids exert their effects. The review also discussed the importance of vitexin and isovitexin in cardiovascular health through the vascular endothelium. In vivo and in vitro studies suggest that vitexin and isovitexin play a cardioprotective role during ischaemia-reperfusion injury and angiogenesis, while isovitexin decreases perfusion pressure and increases the bioavailability of nitric oxide. Taken together, vitexin and isovitexin are promising as therapeutic agents for the formulation of nutraceuticals for the prevention, management, and treatment of cardiovascular diseases.


  • Allergic Effects of Bioactive Peptides Produced from Different Food Sources

    by Sharon O. Azubuike-Osu, Flora-Glad C. Ekezie, Williams E. Ibegbunam, Chibuike C. Udenigwe

    Several food sources contain isolated small fragments of proteins called peptides which provide some beneficial physiological effects to the human body. They serve as potential modifiers reducing the risk of many chronic diseases. However, upon assessment these proteins/peptides may still exert adverse effects in the form of abnormal immunological reactions (food allergy) upon consumption by susceptible patients, thereby limiting their widespread use. Food allergy is a life-threatening condition with growing health concern worldwide. An improvement in the insights on the underlying mechanisms that initiate tolerance and sensitization to allergens through mapping and characterization of epitopes on food allergens has led to a drastic change in the physical and clinical approach to mitigate food allergies. This involves a revolution in the concept of clinical immunotherapies and strategies for the mitigation of food allergies using food processing. As such, processing technologies (e.g., thermal processing, enzymatic hydrolysis, irradiation, high-pressure treatments etc.) are investigated to reduce food allergenicity by conformational changes and as a consequence develop novel hypoallergenic foods products. Although, based on the nature of the allergen, type of processing and intensity of treatment, the allergenicity food peptides/protein, remain unchanged, increase or decrease. In this chapter, we summarize current knowledge on the concept of food allergy, bioactive peptides exerting abnormal immune response and clinical manifestations, associated epitopes and approaches for mapping as well as the impact of food processing on the stability of allergenic peptides.